8-K
filed December 5, 2022, 6:59 PM ET
ticker LNTH
CIK 0001521036
debt
confidence high
sentiment neutral
materiality 0.75
Lantheus Holdings, Inc. (LNTH): debt financing — Lantheus proposes $500M convertible notes due 2027; authorizes up to $150M stock repurchase
Lantheus Holdings, Inc.
- Company proposes $500M in convertible senior notes due 2027, with initial purchasers option for additional $75M.
- Board authorizes $150M in stock repurchases; up to $75M from note proceeds to buy back shares from note purchasers.
- New $350M revolving credit facility and $100M delayed draw term loan refinance existing debt; $167.6M cash used to repay old facility.
- Notes mature Dec 15, 2027, pay semi-annual interest; conversion and redemption features apply.
- Net proceeds for general corporate purposes, including working capital, capex, potential acquisitions, and collaboration payments.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Lantheus Holdings, Inc. incurred term loan of $100.0 million with Lantheus Medical Imaging, Inc. at The Delayed Draw Term Loan Facility includes a commitment fee equal to 0.20% per maturing The commitment of the Lenders to provide the Delayed Draw Term Loan Facility will be terminated upon funding of any such notes..
- Instrument
- term loan
- Principal
- $100.0 million
- Counterparty
- Lantheus Medical Imaging, Inc.
- Rate
- The Delayed Draw Term Loan Facility includes a commitment fee equal to 0.20% per
- Maturity
- The commitment of the Lenders to provide the Delayed Draw Term Loan Facility will be terminated upon funding of any such notes.
- Event
- incurrence
Exact text from the filing
The Credit Agreement establishes (i) a new $100.0 million delayed draw term loan facility (the “ Delayed Draw Term Loan Facility ” and, the loans thereunder, the “ Term Loans ”) and (ii) a new $350.0 million five-year revolving credit facility (the “ New Revolving Facility ” and, together with the Delayed Draw Term Loan Facility, the “ New Facility ”).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Lantheus Holdings, Inc. incurred revolving credit of $350.0 million with Lantheus Medical Imaging, Inc. at The Revolving Loans bear interest, with pricing based from time to time at LMI’s maturing December 2, 2027.
- Instrument
- revolving credit
- Principal
- $350.0 million
- Counterparty
- Lantheus Medical Imaging, Inc.
- Rate
- The Revolving Loans bear interest, with pricing based from time to time at LMI’s
- Maturity
- December 2, 2027
- Event
- incurrence
Exact text from the filing
Under the terms of the New Revolving Facility, the Lenders commit to extend credit to LMI from time to time until December 2, 2027 (the “ Revolving Termination Date ”) consisting of revolving loans (the “ Revolving Loans ”) in an aggregate principal amount not to exceed $350.0 million (the “ Revolving Commitment ”) at any time outstanding, including a $20.0 million sub-facility for the issuance of letters of credit (the “ Letters of Credit ”) and a $10.0 million sub-facility for swingline loans (the “ Swingline Loans ”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lantheus Holdings, Inc. terminated Old Facility with The lenders under the Old Facility valued at Repayment in full of approximately $167.6 million of aggregate remaining principal amount plus inter (effective 2022-12-02).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- The lenders under the Old Facility
- Value
- Repayment in full of approximately $167.6 million of aggregate remaining principal amount plus inter
- Effective
- 2022-12-02
Exact text from the filing
In connection with the Refinancing, effective as of December 2, 2022, LMI has satisfied and discharged all obligations under, and terminated, the Old Facility, except for obligations that pursuant to the express terms of the Old Facility survive payment of the obligations.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Lantheus Holdings, Inc. entered into Credit Agreement with Citizens Bank, N.A. (as administrative agent and collateral agent) and the lenders party thereto valued at $100.0 million delayed draw term loan facility and $350.0 million revolving credit facility (effective 2022-12-02).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Citizens Bank, N.A. (as administrative agent and collateral agent) and the lenders party thereto
- Value
- $100.0 million delayed draw term loan facility and $350.0 million revolving credit facility
- Effective
- 2022-12-02
Exact text from the filing
On December 2, 2022, Lantheus Holdings, Inc.’s (the “ Company ”) wholly-owned subsidiary Lantheus Medical Imaging, Inc. (“ LMI ”) refinanced its existing credit facility, consisting of (i) a $200.0 million five-year term loan facility (the “ Old Term Facility ”) and (ii) a $200.0 million five-year revolving credit facility (the “ Old Revolving Facility ” and, together with the Old Term Facility, the “ Old Facility ”), with a new delayed draw term loan facility and a new revolving credit facility (collectively, these transactions are referred to as the “ Refinancing ”). In order to consummate the Refinancing, LMI entered into a Credit Agreement (the “ Credit Agreement ”) by and among Citizens Bank, N.A., as administrative agent (in that capacity, the “ Administrative Agent ”) and collateral agent, each of the lenders from time to time party thereto (the “ Lenders ”) and the Company. The Credit Agreement establishes (i) a new $100.0 million delayed draw term loan facility (the “ Delayed
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.